HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target

Benzinga · 3d ago
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $120 price target.